BIND Therapeutics (BIND) Misses Q1 EPS by 6c

BIND Therapeutics (NASDAQ: BIND) reported Q1 EPS of ($0.61), $0.06 worse than the analyst estimate of ($0.55). Revenue for the quarter came in at $1.87 million versus the consensus estimate of $3.83 million.

Cash, cash equivalents and short-term investments were approximately $21.5 million as of March 31, 2016. Given the fact that the Company is operating under Chapter 11 bankruptcy protection, the Company is suspending financial runway guidance until further notice.

For earnings history and earnings-related data on BIND Therapeutics (BIND) click here.

You May Also Be Interested In

• Phillip Securities Reiterates Buy Rating on Sea Ltd. (SE)
• Bimergen Energy Corporation (BESS) Reports Q2 EPS of $0.22
• Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance